Cell line · CVCL_0145
Papers69
1 to 20 of 69
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Lipid-Polymeric Nanoencapsulation of Standardized Camellia sinensis Extract Enhances Antiangiogenic Activity and Ocular Biocompatibility. | Chem Biodivers | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Dual impact of EZH1/2-targeted therapy in HTLV-1-associated inflammation: Direct and indirect mechanisms. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Olfactory ensheathing cell-derived extracellular vesicles protect the degenerated retinal pigment epithelium by delivering phagocytosis-related proteins. | Extracell Vesicles Circ Nucl Acids | 2026 | Its Methods give the RRID and name the line | PubMed | |
| FOXO6 inhibits SMURF2-mediated ubiquitination and degradation of NR4A1 to promote retinal pigment epithelial cell ferroptosis in diabetic retinopathy. | J Cell Commun Signal | 2026 | Its Methods give the RRID and name the line | PubMed | |
| An Aggregation-Induced Polymerization Poly(Disulfide)-Drug Nanoplatform for Autoimmune Uveitis Therapy via Inhibiting the cGAS-STING Pathway. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Deep Proteomic Analysis With Machine Learning Identifies Aqueous Humor Biomarkers of ADAMTSL4-associated Congenital Ectopia Lentis. | Invest Ophthalmol Vis Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Activation of AMPK as a therapeutic strategy for FBXL4-related mitochondrial DNA depletion syndrome. | EMBO Mol Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A CRISPR-Cas13d cancer therapeutic enables selective elimination of uveal melanoma. | Mol Ther Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A sequential dual-drug delivery system for multi-target inhibition of subretinal fibrosis. | J Nanobiotechnology | 2026 | Its Methods give the RRID and name the line | PubMed | |
| EFA6A regulates retinal function through the control of photoreceptor cell activity and structure. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| UC2288 decreases the viability and metastatic activity of human Uveal melanoma cells via activating the AMPK/eIF2/ATF4 ER stress axis. | Eur J Pharmacol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Antiproliferative Activity of α-Tocopherol, γ-Tocopherol and Tocotrienols and Their Drug Interactions Evaluated Using Loewe and Chou-Talalay Models in HeLa and MCF-7 Cancer Cell Lines. | Biomedicines | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Fucoidan from Fucus vesiculosus Protects Retinal Pigment Epithelium from Lipid-Induced Damage Related to AMD. | Mar Drugs | 2026 | Its Methods give the RRID and name the line | PubMed | |
| NuSAP Safeguards Centriole Integrity to Mediate CEP57-CEP152 Torus Recruitment for Proper Engagement. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PLGA nanoparticles restore acidic pH and degradative function to compromised lysosomes with Cy3-labeling providing enhanced tracking to lysosomes. | Am J Physiol Cell Physiol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| B7-H3 and GD2 overexpression as immunotherapeutic targets in retinoblastoma. | Sci Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The rs713586 risk variant dysregulates ADCY3 rather than DNAJC27, leading to obesity through ZFP42-TET1-mediated DNA methylation. | EBioMedicine | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CRISPR-Cas13d-Mediated Targeting of a Context-Specific Essential Gene Enables Selective Elimination of Uveal Melanoma. | bioRxiv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| PDZK1 Protects Against RPE Senescence by Targeting the 14-3-3ε-mTOR Axis to Attenuate Early Diabetic Retinopathy. | Adv Sci (Weinh) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| ATXN3 regulates lysosome regeneration after damage by targeting K48-K63-branched ubiquitin chains. | EMBO J | 2025 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0145/papers